EFL1P1: A Potential Drug Target for Various Diseases (G648809)

Target Name: EFL1P1

NCBI ID: G648809

Other Name(s): FAM42B | Elongation factor like GTPase 1 pseudogene 1 | HsT19321 | EFTUD1P1 | elongation factor like GTPase 1 pseudogene 1

EFL1P1: A Potential Drug Target for Various Diseases

EFL1P1 (FAM42B), a protein that belongs to the FAM (FAM1A subfamily) of the serine/threonine protein kinase family, has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to investigate, and its potential as a drug target has led to a number of research studies.

The FAM1A subfamily is a family of proteins that contain a unique catalytic domain, which consists of a nucleotide-binding oligomerization domain (NBO), a serine/threonine kinase domain, and a C-terminal hypervariable region (HVR). The NBO is a The serine/threonine kinase domain is responsible for the catalytic activity of the protein, while the HVR is involved in the regulation of protein function and interactions.

EFL1P1 is a member of the FAM1A subfamily and is expressed in a variety of tissues and organs, including brain, muscle, and plasma. It has been shown to play a role in the regulation of cellular processes, including cell signaling, cell adhesion, and neurotransmission. In addition, EFL1P1 has been shown to be involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key reasons why EFL1P1 has been identified as a potential drug target is its involvement in the regulation of cell signaling pathways. Many diseases, including cancer and neurodegenerative diseases, are characterized by the dysregulation of signaling pathways, which leads to the development of uncontrolled cellular processes. EFL1P1 has been shown to play a role in the regulation of several signaling pathways, including the TGF-β pathway, which is involved in cell signaling and growth, and the NF-kappa-B pathway, which is involved in inflammation and stress responses.

In addition to its involvement in signaling pathways, EFL1P1 has also been shown to be involved in the regulation of cellular processes that are critical for the maintenance of cellular homeostasis. For example, EFL1P1 has been shown to play a role in the regulation of cell adhesion. , which is critical for the maintenance of tissue structure and the development of tissues and organs. Additionally, EFL1P1 has been shown to play a role in the regulation of neurotransmission, which is critical for the function of nervous system and the development of various psychiatric and neurological disorders.

EFL1P1 has also been shown to be involved in the regulation of cellular processes that are critical for the development and progression of diseases. For example, EFL1P1 has been shown to play a role in the regulation of cancer cell growth and progression, and has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. In addition, EFL1P1 has also been shown to play a role in the regulation of autoimmune disorders, which are characterized by the dysregulation of the immune system.

In conclusion, EFL1P1 is a protein that has been identified as a potential drug target or biomarker for a variety of diseases. Its unique structure and function have made it an attractive target for researchers to investigate, and its potential as a drug target has led to a number of research studies. Further research is needed to fully understand the role of EFL1P1 in the regulation of cellular processes and its potential as a drug target.

Protein Name: Elongation Factor Like GTPase 1 Pseudogene 1

More Common Targets